Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Thrombin generation and cell-dependent hypercoagulability in sickle cell disease.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Effects of an acidic environment on coagulation dynamics.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Activation, activity and inactivation of factor VIII in factor VIII products.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Journal of thrombosis and haemostasis : JTH·2015
Same author

The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood: comment.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.

Journal of thrombosis and haemostasis : JTH·2014

関連する実験動画

Updated: Jun 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

口服用抗凝固剤の値について

K E Brummel1, S G Paradis, R F Branda

  • 1Department of Biochemistry, Given Building, Health Science Complex University of Vermont, College of Medicine, Burlington, USA.

Circulation
|November 7, 2001
PubMed
まとめ

ワルファリン治療は,同様の国際標準比率 (INR) にもかかわらず,血の凝固時間およびトロンビン-アンチトロンビンIII (TAT) プロフィールにおいて有意な変動を示しています. これは,抗凝固制御が予想より安全でない可能性を示唆し,個々の反応が出血と凝固のリスクに影響を与える.

科学分野:

  • 血液学 ヘマトロジ
  • 薬理学 薬理学とは
  • クリニカル・メディシン 臨床医学

背景:

  • 口服抗凝固剤のモニタリングは,出血と血栓の予防に不可欠です.
  • ワルファリン治療は,治療効果を維持するために慎重に管理する必要があります.
  • 抗凝固剤に対する個々の患者の反応は,著しく異なる可能性があります.

研究 の 目的:

  • ワルファリン療法を受けた患者で,同様の国際標準比率 (INR) を有する全血凝固を調査する.
  • 凝固プロファイルとトロンビン-アンチトロンビンIII (TAT) 生成の変動性を評価する.
  • INR,凝固パラメータ,およびファクターVIIIレベルとの関係を調査する.

主な方法:

  • ワルファリンを投与した8人の男性 (グループW) と,複数回投与した1人の男性 (被験者A) で,組織因子誘発全血凝固を研究した.
  • 測定された凝固時間,トロンビン-アンチトロンビンIII (TAT) 形成率およびレベル,血小板活性化,およびフィブリンペプチドA生成.
  • ファクターVIIIのレベルを評価し,ワルファリン治療の年数と相関させた.

主要な成果:

  • 類似のINRを持つ被験者は,凝固時間 (6.2〜23分) とTATプロファイルの大きな変化を示しました.

さらに関連する動画

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

関連する実験動画

Last Updated: Jun 28, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

  • 正常な対照群は,より短い凝固時間 (5.7±0.3分) と,より高いTATレベル (742±91 nmol/L) を示した.
  • Wグループ (204±34.4%) のVIII因子レベルは,対照群 (149.4±37.4%) と比較して,ワルファリン治療の持続時間 (r=0.78,P=0.01) と相関して有意に増加しました.

    • 結論:

    • 設定されたINRの治療範囲への抗凝固剤のコントロールは,想定よりも安全ではないかもしれません.
    • 組織因子凝固反応の個別の有意な変動は,類似のINRを持つ患者の間で存在します.
    • この変動性は,出血と血栓の異なるリスクを示唆し,潜在的に基礎となる血管異常と,増加したファクターVIIIのような補償メカニズムに関連しています.